Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase ...

At the Guggenheim Securities Healthcare Innovation Conference, Altimunne said earlier: “So the first thing is that survodutide has a ratio of GLP-1/glucagon of 8 to 1. It’s much more heavily biased to ...

Boehringer Ingelheim today announced that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated ...